The 11th Pacific Forum of the US-China Biomedical and Pharmaceutical Professional Association (SABPA) was held on September 26 at the Delmareleyton Hotel in Santiago. About 500 representatives from more than 50 biotechnology companies, pharmaceutical companies, investment or service agencies from the United States and China attended the forum. Mr. Lv Xianzhi, the science and technology counselor of the Chinese Consulate in Los Angeles, Dr. Lu Xianping, the president of Shenzhen microchip biotech co., ltd., Dr. Zhang Fangning from McKinsey's Shanghai office, Dr. Zhang Zhimin, the vice president of Johnson innovation center, and other guests delivered their speech. Dr. Shi Tao, the chairman of SABPA Pacific Alliance, and Dr. Zhang Mingzhu, the former chairman of SABPA, delivered opening welcoming remarks and closing remarks respectively.

In the afternoon, the first part was the SABPA Pacific Ocean Life Science Achievement Award presentation ceremony. This award-winning guest is Dr. Lu Xianping, the president of Shenzhen CHIPSCREEN BIOSCIENCES co., ltd., and Zhu Huichun, the executive director and former president of SABPA Council presented the award. After accepting this award, Dr. Lu delivered an acceptance speech. He reviewed the development of CHIPSCREEN BIOSCIENCES, especially the successful independent development of a new anti-tumor epigenetic regulatory drug, Chidamide. Chidamide is an anti-tumor oral drug, which is mainly aimed at relapsing and refractory peripheral T-cell lymphoma and has been authorized by global patents. It is the fastest developing oral dosage form subtype selective histone deacetylase inhibitor in the world. Compared with previous broad-spectrum inhibitors, it has much weaker cytotoxicity and higher epigenetic control effect.

Zhu Huichun, the executive director and former president of SABPA Council presented the award to Dr. Lu(on the right), the president of Shenzhen CHIPSCREEN BIOSCIENCES co.,

During the meeting, San Diego Chinese online reporters interviewed Dr. Lu Xianping, the president of Shenzhen CHIPSCREEN BIOSCIENCES co., ltd., the award-winning guest of SABPA Pacific Life and Science Achievement Award, on the prospect of the cooperative pharmaceutical industry in the United States and the Pacific, how to continuously pursue low consumer prices and affordable pharmaceutical products.

Qian Xu, an internationally renowned Chinese scientist who won seven US national science awards in 2011, who is the Academician of the US Academy of Sciences, Academician of the Chinese Academy of Sciences and Foreign Academician of the Chinese Academy of Sciences, and the currently dean of Whitaker Biomedical Engineering Research Institute of the University of California at San Diego, was also awarded the San Diego biomedical achievement award by SABPA in 2008.